ASEANEWS HEADLINE-HEALTH | ASIA: New COVID Wave In Asia Linked To JN.1 Strain: What You Need To Know About The Variant
What is the JN.1 Covid Variant? Check the List of Affected Countries Here
What is the JN.1 Covid Variant? Check the List of Affected Countries
As parts of Asia grapple with a fresh surge of COVID-19 cases, a familiar but concerning player has re-emerged—JN.1, a subvariant of the Omicron lineage. From Singapore and Hong Kong to Thailand and potentially India, this new wave is raising global alarms as infections mount and health systems brace for impact. Here’s a deep dive into what’s driving this resurgence, what we know about the JN.1 strain, and what it means for the months ahead.
COVID-19 cases are climbing rapidly in several Asian countries. Singapore has reported a significant jump—from 11,100 infections in the last week of April to over 14,200 in early May 2025. Daily hospitalizations have also increased, from an average of 102 to 133 within the same timeframe, although ICU admissions have slightly decreased.
|
|
Ads by:
…
Covid-19 JN.1 variant spreads in Asia: Should India be worried as cases rise in Singapore?
Covid cases surge in Singapore due to JN.1 variant. What it means for India, symptoms, vaccine response, and p..
.
Credits: Sanjay Rawat
.
In Hong Kong, public health authorities are observing the highest percentage of positive respiratory samples for COVID-19 in over a year. The Centre for Health Protection has confirmed that the virus is “spreading quite high,” hinting at a potential wave reminiscent of previous surges.
India, for now, is reporting only 93 active cases as of May 19. But leading Indian doctors are cautioning that a spike may be imminent, pointing to waning immunity in the population and drawing parallels with patterns seen in other Asian nations.
JN.1 and Its Descendants
The main drivers behind this new wave are sub-variants of Omicron, particularly LF.7 and NB.1.8—both direct descendants of JN.1. This makes JN.1 and its lineage central to understanding the current outbreak dynamics.
|
|
First detected in August 2023 and labeled a Variant of Interest by the World Health Organization in December, JN.1 is a sub-lineage of BA.2.86, also known as Pirola. With nearly 30 mutations in its spike protein, JN.1 was designed—so to speak—to outmaneuver both immunity and vaccines. Its capacity to spread swiftly was evident when it quickly became the dominant strain in the United States by January 2024.
How Is JN.1 Different And Dangerous?
JN.1 differs from its parent variant Pirola by one key mutation in its spike protein, which may further enhance its ability to evade immune defenses. Despite this, current evidence suggests it does not cause more severe illness than previous variants. The symptoms remain familiar—fever, dry cough, shortness of breath, fatigue, sore throat, and runny nose—and are largely influenced by individual immunity rather than the virus itself.
|
|
The variant’s real power lies in its speed. In the U.S., it went from causing 3.5% of cases in November 2023 to over 85% by mid-January 2024. This exponential growth pattern is now being mirrored in Asia.
What This Means for India and the Rest of the World?
|
Country
|
Recent Trends & Data
|
Response Measures
|
|
Hong Kong
|
Highest percentage of Covid-positive respiratory samples in a year; 31 severe cases reported in one week
|
Health authorities on alert; monitoring sewage data
|
|
Singapore
|
28% increase in cases (14,200 in one week); hospitalizations up 30%
|
Released official figures; monitoring closely
|
|
Thailand
|
Cases doubled to 33,030 in one week; most cases in Bangkok and nearby provinces
|
Urging booster vaccinations, especially for high-risk groups
|
|
China
|
Covid positivity rate in outpatient/emergency cases rose from 7.5% to 16.2% (Mar 31–May 4)
|
Monitoring for a possible new wave
|
|
257 active cases reported recently; no outbreak yet
|
Authorities closely monitoring the situation
|
.
Related Stories
The resurgence of JN.1-driven cases raises pressing questions about population immunity, vaccine effectiveness, and the risk of long COVID. While India’s current caseload is low, past trends indicate the country may not remain insulated for long. With antibody levels dropping post-vaccination or infection, the population may be vulnerable.
|
|
Public health authorities are now more focused on monitoring hospitalizations and severe cases rather than overall infection numbers. The good news? Vaccines, especially updated versions released in fall 2024, are expected to offer protection against JN.1. COVID-19 tests, including rapid antigen and PCR methods, can still detect the virus effectively.
How To Stay Protected?
Vaccination remains the first line of defense. Updated COVID-19 shots are available for those aged 6 months and above and are recommended as a seasonal precaution—particularly as JN.1 spreads globally. Additional RSV and flu shots are available for vulnerable groups, helping shield populations from the feared “tripledemic.”
|
|
Beyond vaccines, standard COVID precautions still hold weight:
- Masking in crowded or poorly ventilated spaces
- Hand hygiene
- Avoiding contact with symptomatic individuals
- Monitoring local transmission levels
For those infected, symptoms usually appear within 2 to 14 days post-exposure and can last days to weeks. If symptoms persist, particularly fatigue or breathing difficulty, it may signal long COVID—a condition that requires medical attention.
PREVENT CLIMATE CHANGE
Memento Maxima Digital Marketing
@[email protected]
SPACE RESERVE FOR ADVERTISEMENT
.
